2022
A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design
Albers G, Campbell B, Lansberg M, Broderick J, Butcher K, Froehler M, Schwamm L, Nouh A, Liebeskind D, Toy F, Yang M, Massaro L, Schoeffler M, Purdon B. A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design. International Journal Of Stroke 2022, 18: 237-241. PMID: 35262424, DOI: 10.1177/17474930221088400.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeInternal carotid arteryPlacebo-controlled trialRankin Scale scoreSymptom onsetDay 90Scale scoreMiddle cerebral artery occlusionEfficacy of tenecteplaseLate-window patientsSafety of tenecteplaseSymptomatic intracranial hemorrhageCerebral artery occlusionLarge vessel occlusionPhase IIIPrimary efficacy objectiveBetter clinical outcomesAdverse eventsArtery occlusionEndovascular thrombectomyIschemic strokeMCA occlusionClinical outcomesIntracranial hemorrhageSalvageable tissue
2021
Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease
Bernstein R, Kamel H, Granger C, Piccini J, Sethi P, Katz J, Vives C, Ziegler P, Franco N, Schwamm L, Acosta I, Jamnadas P, Manda S, Alimohammad R, Arias V, Tempro K, Ward K, Asi K, Choudhuri I, Guerrero W, Kalia J, Niazi I, Sajjad R, Thavapalan V, Assar M, Banchs J, Black J, Cheung P, Donsky A, Graybeal D, Hasan R, Mir O, Nguyen C, Olsovsky G, Rasmussen J, Hasabnis S, Reeves R, Rowley C, Sharma J, Smith M, Bonyak K, Sackett M, Allred J, Sethi P, Jung R, Lynch J, Rowe S, Dash S, Glotzer T, Jamal S, Radoslovich G, Shukla G, Zimmerman J, Hussein H, Zhu D, Krueger K, Ostrander M, Ramirez D, Shultz J, Simonson J, Cucchiara B, Deo R, Frankel D, Jia J, Kasner S, Luciano J, Messe S, Mullen M, Santangeli P, Schaller R, Yuan Q, Bledsoe D, Cajavilca C, Chiu D, Gadhia R, Grimes M, Katz L, Moye S, Rami T, Thomas A, Volpi J, Al Balushi A, Boyd C, Choudry S, Dhamoon M, Dukkipati S, Goltz D, Hao Q, Horowitz D, Kaur G, Koruth J, Kurian C, Langan M, Matos Diaz I, Miller M, Reddy V, Sheinart K, Stein L, Tansy A, Tuhrim S, Weinberger J, Whang W, Cross J, Kreger H, Saltzman M, Zide K, Bansal S, Bernabei M, Flaster M, Barrett C, Etherton M, Heist E, Lubitz S, Regenhardt R, Sharma R, Silverman S, Sloane K, Viswanathan A, Doshi A, Logan W, Malik M, Rempe D, Arora R, Beldner S, Epstein L, Ismail H, Jadonath R, Katz J, Libman R, Moussavi M, Patel A, Patel A, Willner J, Wright P, Caprio F, Kim S, Mendelson S, Passman R, Ruff I, Alsorogi M, Chaudhary G, Morris K, Mullins S, Talpur N, Thomas K, Chancellor B, Chinitz L, Culpepper A, Fara M, Ishida K, Lillemoe K, Lord A, Torres J, Zhang C, Abi-Samra F, Bernard M, Carter J, Chokhawala H, Downey A, Khatib S, Morin D, Polin G, Rogers P, Vidal G, Zweifler R, Belt G, Felberg R, Furer S, Hanna J, McCall-Brown A, Seeger S, Reddy R, Skalabrin E, Soik D, Wilder M, Kearney M, LaFranchise E, Parker B, Pickett R, Bonaguidi H, Gibson D, Kalafut M, Mattera B, Olson N, Parker M, Rogers J, Uddin P, Chang C, Graner S, Kipta J, Salem R, Singh D, Al-Awwad A, Beaver B, Chaudhary S, Clayton S, Delpirou Nouh C, Garabelli P, Gordon D, Pakala A, Ray B, Saucedo S, Sidorov E, Stavrakis S, Ching M, Deline C, Hourihane J, Kandel A, Kim C, Magun R, Mowla A, Sawyer R, Switzer D, Badhwar N, Lee R, Meisel K, Smith W, Alkahalifah M, Aroor S, Asdaghi N, Bhatt N, Del Brutto V, Dillon G, Gadient P, Koch S, Lambrakos L, Malik A, Marulanda-Londono E, Memon Z, Mendoza I, Mitrani R, Ortiz G, Ramano J, Sur N, Torres L, Daniels J, Johnson M, Magadan A, Shang T, Mcclelland N, Merriam T, Neisen K. Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease. JAMA 2021, 325: 2169-2177. PMID: 34061145, PMCID: PMC8170544, DOI: 10.1001/jama.2021.6470.Peer-Reviewed Original ResearchConceptsSmall vessel diseaseAtrial fibrillationUsual careCardiac monitoringIndex strokeICM groupControl groupAdditional stroke risk factorsProcedure-related adverse eventsAF incidence ratesMore atrial fibrillationCHA2DS2-VASc scorePrimary end pointStroke risk factorsIncident atrial fibrillationMulticenter clinical trialAF detectionContinuous cardiac monitoringLong-term cardiac monitoringEligible patientsAdverse eventsIschemic strokeHolter monitoringRisk factorsClinical trialsOral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation
Saeed O, Zhang S, Patel S, Jorde U, Garcia M, Bulcha N, Gupta T, Xian Y, Matsouaka R, Shah S, Smith E, Schwamm L, Fonarow G. Oral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation. Journal Of Cardiac Failure 2021, 27: 857-864. PMID: 33975786, PMCID: PMC8355019, DOI: 10.1016/j.cardfail.2021.02.017.Peer-Reviewed Original ResearchConceptsOral anticoagulationRecurrent ischemic strokeAcute ischemic strokeIschemic strokeHeart failureAtrial fibrillationOlder patientsHistory of HFInitiation of OACCox proportional hazard ratiosProportional hazard ratiosHeart failure patientsKaplan-Meier curvesClinical registry dataCause bleedingEligible patientsAdverse eventsCumulative incidenceFailure patientsHazard ratioSuch patientsYear mortalityAdverse outcomesClinical covariatesRegistry data
2019
Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice
Jahan R, Saver J, Schwamm L, Fonarow G, Liang L, Matsouaka R, Xian Y, Holmes D, Peterson E, Yavagal D, Smith E. Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice. JAMA 2019, 322: 252-263. PMID: 31310296, PMCID: PMC6635908, DOI: 10.1001/jama.2019.8286.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeEndovascular reperfusion therapySymptomatic intracranial hemorrhageLarge vessel occlusionRoutine clinical practiceHospice dischargePuncture timeClinical practiceSubstantial reperfusionIschemic strokeArterial punctureVessel occlusionLarge vessel occlusion acute ischemic strokeMedian pretreatment scoreHealth Stroke ScaleRetrospective cohort studyRandomized clinical trialsHigher likelihoodAssociation of speedAmbulatory statusReperfusion therapyStroke ScaleAdverse eventsCohort studyHospital arrival
2018
Safety and Efficacy of a 3-Dimensional Stent Retriever With Aspiration-Based Thrombectomy vs Aspiration-Based Thrombectomy Alone in Acute Ischemic Stroke Intervention: A Randomized Clinical Trial
Nogueira R, Frei D, Kirmani J, Zaidat O, Lopes D, Turk A, Heck D, Mason B, Haussen D, Levy E, Mehta S, Lazzaro M, Chen M, Dörfler A, Yoo A, Derdeyn C, Schwamm L, Langer D, Siddiqui A. Safety and Efficacy of a 3-Dimensional Stent Retriever With Aspiration-Based Thrombectomy vs Aspiration-Based Thrombectomy Alone in Acute Ischemic Stroke Intervention: A Randomized Clinical Trial. JAMA Neurology 2018, 75: 304-311. PMID: 29296999, PMCID: PMC5885851, DOI: 10.1001/jamaneurol.2017.3967.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeSerious adverse eventsProcedure-related serious adverse eventsStent retrieverMechanical thrombectomy devicesAspiration groupAdverse eventsEnd pointClinical trialsThrombectomy devicesLarge vessel acute ischemic strokeDevice-related serious adverse eventsScale scoreHealth Stroke Scale scoreMedian baseline NIHSS scorePrimary effectiveness end pointPrimary safety end pointAcute ischemic stroke interventionCerebral infarction (TICI) gradeEffectiveness end pointBaseline NIHSS scorePrimary end pointSafety end pointStroke Scale scoreHours of onset
2017
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke
Xian Y, Federspiel J, Hernandez A, Laskowitz D, Schwamm L, Bhatt D, Smith E, Fonarow G, Peterson E. Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke. Circulation 2017, 135: 1024-1035. PMID: 28119380, DOI: 10.1161/circulationaha.116.023940.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAgedAged, 80 and overAnticoagulantsDabigatranFemaleFibrinolytic AgentsHemorrhageHospital MortalityHumansInternational Normalized RatioMalePyrazolesPyridonesRecombinant ProteinsRegistriesRetrospective StudiesRisk FactorsRivaroxabanStrokeTime FactorsTissue Plasminogen ActivatorTreatment OutcomeWarfarinConceptsIntravenous rt-PASymptomatic intracranial hemorrhageIschemic strokeRt-PAIntracranial hemorrhageOdds ratioNon-Vitamin K Antagonist Oral AnticoagulantsIntravenous recombinant tissue plasminogen activatorK Antagonist Oral AnticoagulantsRecombinant tissue plasminogen activatorGuidelines-Stroke registrySerious systemic hemorrhageAcute ischemic strokeAdjusted odds ratioAmerican Heart AssociationTissue plasminogen activatorOutcomes of useHospital mortalityRegistry hospitalsOral anticoagulantsSevere strokeAdverse eventsProhibitive riskRankin ScaleThrombolytic therapy
2016
Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke
von Kummer R, Mori E, Truelsen T, Jensen J, Grønning B, Fiebach J, Lovblad K, Pedraza S, Romero J, Chabriat H, Chang K, Dávalos A, Ford G, Grotta J, Kaste M, Schwamm L, Shuaib A, Albers G. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke. Stroke 2016, 47: 2880-2887. PMID: 27803391, DOI: 10.1161/strokeaha.116.013715.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsSymptomatic intracranial hemorrhageSerious adverse eventsAdverse eventsMRS scoreTreatment armsIntracranial hemorrhagePooled analysisDay 90Major artery occlusionIschemic stroke patientsRankin Scale scoreMajor cerebral arteriesHigh-grade stenosisSignificant clinical benefitExtended time windowIntravenous desmoteplaseArterial recanalizationArtery occlusionIntravenous treatmentIschemic strokePrimary outcomeCerebral arteryRecanalization rateStroke patients
2015
Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial
Albers G, von Kummer R, Truelsen T, Jensen J, Ravn G, Grønning B, Chabriat H, Chang K, Davalos A, Ford G, Grotta J, Kaste M, Schwamm L, Shuaib A, Investigators D. Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet Neurology 2015, 14: 575-584. PMID: 25937443, DOI: 10.1016/s1474-4422(15)00047-2.Peer-Reviewed Original ResearchConceptsMajor cerebral arteriesHigh-grade stenosisRankin Scale scoreIschemic strokeSymptom onsetCerebral arteryDay 90Scale scorePlacebo-controlled phase 3 trialComputer-generated randomisation listMajor cerebral artery occlusionModified Rankin Scale scoreSymptomatic cerebral edemaSymptomatic intracranial hemorrhageBaseline National InstitutesHealth Stroke ScaleSerious adverse eventsCerebral artery occlusionPhase 3 trialModified Rankin ScaleRandomisation listStroke ScaleStudy drugAdverse eventsArtery occlusion
2012
M. D. Hammer et al.
Hammer M, Schwamm L, Starkman S, Schellinger P, Jovin T, Nogueira R, Burgin W, Sen S, Diener H, Watson T, Michel P, Shuaib A, Dillon W, Liebeskind D. M. D. Hammer et al. International Journal Of Stroke 2012, 7: 655-661. PMID: 22264202, PMCID: PMC4157918, DOI: 10.1111/j.1747-4949.2011.00719.x.Peer-Reviewed Original ResearchConceptsIschemic stroke patientsSymptom onsetPartial aortic occlusionStroke patientsAortic occlusionIntracranial hemorrhageEight hoursInternational academic medical centersAsymptomatic intracranial hemorrhageLower baseline NIHSSSymptomatic intracranial hemorrhageFavorable neurological outcomeHealth Stroke ScalePerfusion-diffusion mismatchSingle-arm trialAcademic medical centerMagnetic resonance imagingBaseline NIHSSNeurological outcomeParenchymal hematomaStroke ScaleAdverse eventsSecondary outcomesStroke severityAcute treatment